Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,186.96 -0.74 (-0.01%) Dow
38,930.59 +46.33 (+0.12%) Nasdaq
16,324.24 -8.32 (-0.05%) Bitcoin USD
62,647.23 -788.24 (-1.24%) CMC Crypto 200
1,328.04 +33.37 (+2.58%)
Vistagen Therapeutics, Inc. (VTGN)
| Previous close | 4.6600 |
| Open | 4.6600 |
| Bid | 4.5800 x 100 |
| Ask | 4.6700 x 300 |
| Day's range | 4.5900 - 4.6600 |
| 52-week range | 1.6200 - 24.7100 |
| Volume | |
| Avg. volume | 264,177 |
| Market cap | 124.856M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings date | 26 Jun 2024 - 01 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14 and 15, 2024 in New York City.
Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
SOUTH SAN FRANCISCO, Calif., April 25, 2024--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo a
Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine c
